X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7408) 7408
Publication (838) 838
Book Review (705) 705
Newsletter (258) 258
Conference Proceeding (51) 51
Newspaper Article (34) 34
Book Chapter (31) 31
Magazine Article (20) 20
Dissertation (7) 7
Transcript (4) 4
Data Set (2) 2
Trade Publication Article (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5257) 5257
index medicus (5197) 5197
ritonavir (3801) 3801
hiv infections - drug therapy (3453) 3453
male (3060) 3060
female (2715) 2715
infectious diseases (2530) 2530
adult (2515) 2515
pharmacology & pharmacy (2058) 2058
hiv (1922) 1922
ritonavir - therapeutic use (1853) 1853
middle aged (1826) 1826
protease inhibitors (1540) 1540
drug therapy, combination (1537) 1537
hiv protease inhibitors - therapeutic use (1516) 1516
immunology (1437) 1437
ritonavir - administration & dosage (1410) 1410
lopinavir (1366) 1366
aids/hiv (1360) 1360
anti-hiv agents - therapeutic use (1295) 1295
antiretroviral therapy (1285) 1285
virology (1154) 1154
hiv infections - virology (1050) 1050
pharmacokinetics (1046) 1046
drug therapy (1027) 1027
ritonavir - adverse effects (1016) 1016
viral load (995) 995
treatment outcome (954) 954
drug interactions (952) 952
antiviral agents (936) 936
human immunodeficiency virus--hiv (927) 927
hiv protease inhibitors - administration & dosage (910) 910
hiv protease inhibitors - adverse effects (859) 859
microbiology (858) 858
antiretroviral drugs (829) 829
hiv-1 - drug effects (827) 827
anti-hiv agents - administration & dosage (815) 815
therapy (803) 803
hiv infection (784) 784
ritonavir - pharmacology (755) 755
cd4 lymphocyte count (724) 724
ritonavir - pharmacokinetics (719) 719
hiv protease inhibitors - pharmacology (686) 686
hiv protease inhibitors - pharmacokinetics (670) 670
lopinavir/ritonavir (669) 669
anti-hiv agents - adverse effects (648) 648
efficacy (618) 618
hiv-1 (596) 596
saquinavir (591) 591
indinavir (589) 589
aids (585) 585
safety (581) 581
research (571) 571
highly active antiretroviral therapy (551) 551
infection (544) 544
darunavir (543) 543
adolescent (536) 536
antiretroviral therapy, highly active (536) 536
aged (529) 529
animals (507) 507
health aspects (505) 505
human-immunodeficiency-virus (489) 489
proteases (489) 489
tenofovir (488) 488
dosage and administration (481) 481
rna, viral - blood (478) 478
drug combinations (477) 477
drug administration schedule (476) 476
atazanavir sulfate (473) 473
protease inhibitor (473) 473
anti-hiv agents - pharmacokinetics (465) 465
hiv-1 - genetics (456) 456
efavirenz (451) 451
analysis (448) 448
reverse transcriptase inhibitors - therapeutic use (444) 444
young adult (443) 443
hiv infections - complications (442) 442
human immunodeficiency virus (437) 437
pyrimidinones - therapeutic use (426) 426
nelfinavir (421) 421
pharmacology (415) 415
hiv infections - immunology (412) 412
hiv-infected patients (412) 412
risk factors (410) 410
hiv infections - blood (408) 408
atazanavir (407) 407
drugs (406) 406
care and treatment (403) 403
abridged index medicus (384) 384
combination (384) 384
active antiretroviral therapy (380) 380
clinical trials (380) 380
sulfonamides - therapeutic use (379) 379
virus diseases (376) 376
prospective studies (374) 374
resistance (363) 363
hiv-1-infected patients (360) 360
genotype (354) 354
in-vitro (343) 343
pyridines - therapeutic use (339) 339
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7394) 7394
Spanish (166) 166
French (77) 77
German (52) 52
Japanese (17) 17
Portuguese (14) 14
Russian (11) 11
Chinese (10) 10
Hungarian (7) 7
Czech (5) 5
Italian (4) 4
Korean (4) 4
Danish (2) 2
Dutch (2) 2
Hebrew (1) 1
Serbian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 2/2012, Volume 54, Issue 3, pp. 414 - 423
Background. This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and... 
Statistical median | HIV/AIDS | HIV | Memory interference | Drug interactions | Medications | Methadone | Pharmacokinetics | Dosage | Data ranges | Opioid analgesics | INFECTIOUS DISEASES | GLUCURONIDATION | VALIDATION | MICROBIOLOGY | OPIOID DEPENDENCE | DARUNAVIR/RITONAVIR | OPIATE WITHDRAWAL | IMMUNOLOGY | DRUG-DRUG INTERACTION | NORBUPRENORPHINE | PHARMACOKINETICS | METHADONE | IN-VIVO | History, 17th Century | Narcotic Antagonists - administration & dosage | Darunavir | Area Under Curve | Buprenorphine - blood | Protease Inhibitors - pharmacokinetics | Humans | Half-Life | Buprenorphine - pharmacokinetics | Male | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Anti-HIV Agents - administration & dosage | Sulfonamides - blood | Drug Interactions | Buprenorphine - analogs & derivatives | Protease Inhibitors - administration & dosage | Female | Opiate Substitution Treatment | Anti-HIV Agents - blood | Narcotic Antagonists - pharmacokinetics | Organophosphates - administration & dosage | Organophosphates - pharmacokinetics | Ritonavir - administration & dosage | Organophosphates - blood | Ritonavir - blood | History, 16th Century | Carbamates - blood | Sulfonamides - pharmacokinetics | Buprenorphine - administration & dosage | Ritonavir - pharmacokinetics | Naloxone - pharmacology | Anti-HIV Agents - pharmacokinetics | Protease Inhibitors - blood | Sulfonamides - administration & dosage | Usage | Fosamprenavir | Dosage and administration | Buprenorphine | Protease inhibitors | Substance abuse treatment | Metabolites | Human immunodeficiency virus--HIV | Pain management | Index Medicus | AIDS
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 2014, Volume 28, Issue 15, pp. 2269 - 2279
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9568, pp. 1169 - 1178
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 05/2016, Volume 10, pp. 1589 - 1603
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 08/2009, Volume 23, Issue 13, pp. 1679 - 1688
Objective: Present 96-week data from ongoing ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In Naive Subjects) trial. Methods: Randomized, open-label,... 
Clinical trials | Darunavir | HIV | Protease inhibitors | Lopinavir | Antiretroviral therapy | INFECTIOUS DISEASES | EFFICACY | SAFETY | antiretroviral therapy | IMMUNOLOGY | ADHERENCE | HIV-INFECTED PATIENTS | DARUNAVIR-RITONAVIR | VIROLOGY | lopinavir | TREATMENT-EXPERIENCED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | protease inhibitors | RESISTANCE | clinical trials | darunavir | 800/100 MG | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Viral Load | HIV Infections - immunology | Ritonavir - adverse effects | HIV-1 - isolation & purification | Ritonavir - therapeutic use | Adult | Female | Antiretroviral Therapy, Highly Active - methods | HIV Protease Inhibitors - adverse effects | Drug Administration Schedule | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Drug Resistance, Multiple, Viral | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Sulfonamides - administration & dosage | Emtricitabine | RNA | Ritonavir | Exanthema | Diarrhea | Data processing | Lipids | Triglycerides | Statistics | Cholesterol | CD4 antigen | Index Medicus | AIDS/HIV
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2014, Volume 54, Issue 8, pp. 949 - 957
This study compared the bioavailability of two candidate fixed-dose combinations (FDCsG003 and G004) of darunavir/cobicistat 800/150 mg with that of darunavir... 
fixed‐dose combination | darunavir | cobicistat | bioavailability | pharmacoenhancer | fixed-dose combination | EFFICACY | SAFETY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | PROTEASE INHIBITORS | TREATMENT-NAIVE | HIV | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | ONCE-DAILY DARUNAVIR/RITONAVIR | Thiazoles - blood | Darunavir | Humans | Middle Aged | Biological Availability | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Young Adult | Sulfonamides - blood | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ritonavir - administration & dosage | Ritonavir - blood | Carbamates - blood | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Cross-Over Studies | Ritonavir - pharmacokinetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cobicistat | Drug Combinations | Sulfonamides - administration & dosage | Usage | Dosage and administration | Drug therapy, Combination | Pharmacokinetics | Analysis | Short term | Index Medicus
Journal Article
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 04/2011, Volume 154, Issue 7, pp. 445 - 456
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article